Evidence map›Paper›PMID 41222740›Full record

ArticleAngiogenesis2025

BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.

Benjamin J Dunmore, Stephen Moore, Rowena J Jones, Joshua Hodgson, Kathryn Auckland, Mark Southwood, Nichola Figg, Nobuhiro Kikuchi, Martin Bennett, Allan Lawrie and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angiogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Benjamin J Dunmore *Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK. bjd28@cam.ac.uk.
Stephen Moore *Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Rowena J JonesVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Joshua HodgsonVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Kathryn AucklandVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Mark SouthwoodMRC Toxicology Unit, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR, UK.
Nichola FiggVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Nobuhiro KikuchiVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Martin BennettVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Allan LawrieNational Heart and Lung Institute, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Christopher J RhodesNational Heart and Lung Institute, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Mark R ToshnerVictor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Stefan Gräf *Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Wei Li *Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Nicholas W Morrell *Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
Paul D Upton *Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, CB2 0BB, UK.
UK National Cohort Study of Idiopathic and Heritable PAH Consortium
Uniphy Clinical Trials Network

Funding

British Heart Foundation FS/18/52/33808British Heart Foundation RG/19/3/34265British Heart Foundation RG71070 and RG8455British Heart Foundation SP/12/12/29836Medical Research Council MR/K020919/1
6 · The paper itself

Abstract

Deleterious mutations in the GDF2 gene, encoding BMP9, are causative of pulmonary arterial hypertension and hereditary haemorrhagic telangiectasia. Paradoxically, BMP9 germ-line knockout (Gdf2

Indexed as

Growth Differentiation Factor 2Muscle, Smooth, VascularPulmonary ArteryTamoxifenVascular RemodelingAnimalsHumansMiceMice, KnockoutMyocytes, Smooth MuscleGdf2 protein, mouseGrowth Differentiation Factor 2TamoxifenBone morphogenetic proteinPulmonary arterial hypertensionPulmonary vascular remodellingTamoxifen

Identifiers

PMID41222740
PMCPMC12611992

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.